[go: up one dir, main page]

MX2016015346A - Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. - Google Patents

Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.

Info

Publication number
MX2016015346A
MX2016015346A MX2016015346A MX2016015346A MX2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A MX 2016015346 A MX2016015346 A MX 2016015346A
Authority
MX
Mexico
Prior art keywords
death
radiotherapy
combination
cancer treatment
treatment methods
Prior art date
Application number
MX2016015346A
Other languages
English (en)
Other versions
MX382472B (es
Inventor
Morrow Michelle
Stewart Ross
DOVEDI Simon
Illidge Tim
Wilkinson Robert
Poon Edmund
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53498965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016015346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2016015346A publication Critical patent/MX2016015346A/es
Publication of MX382472B publication Critical patent/MX382472B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta solicitud proporciona un método para tratar cáncer en un paciente que comprende administrar al menos una dosis de radioterapia y al menos un antagonista de PD-1 y/o PD-L1, en el que al menos un antagonista de PD-1 y/o PD-L1 se administra el mismo día que una dosis de radioterapia o hasta e incluyendo 4 días después.
MX2016015346A 2014-06-17 2015-06-17 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinación con radioterapia. MX382472B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013157P 2014-06-17 2014-06-17
PCT/EP2015/063552 WO2015193352A1 (en) 2014-06-17 2015-06-17 Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Publications (2)

Publication Number Publication Date
MX2016015346A true MX2016015346A (es) 2017-08-10
MX382472B MX382472B (es) 2025-03-13

Family

ID=53498965

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016015346A MX382472B (es) 2014-06-17 2015-06-17 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinación con radioterapia.
MX2021004821A MX2021004821A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2021004828A MX2021004828A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021004821A MX2021004821A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2021004828A MX2021004828A (es) 2014-06-17 2016-11-23 Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.

Country Status (19)

Country Link
US (2) US10092645B2 (es)
EP (2) EP4144412A1 (es)
JP (5) JP6877147B2 (es)
KR (4) KR20230113847A (es)
CN (1) CN107073107A (es)
AU (3) AU2015276173B2 (es)
BR (1) BR112016028964A2 (es)
CA (1) CA2950046C (es)
DK (1) DK3157629T3 (es)
ES (1) ES2933603T3 (es)
HU (1) HUE060689T2 (es)
IL (1) IL249133B (es)
MX (3) MX382472B (es)
PL (1) PL3157629T3 (es)
PT (1) PT3157629T (es)
RU (1) RU2711408C2 (es)
SG (2) SG11201610600SA (es)
TW (2) TWI781021B (es)
WO (1) WO2015193352A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292193B2 (en) * 2013-09-11 2024-11-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
JP6829193B2 (ja) * 2014-10-27 2021-02-10 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんを治療するための単独または併用療法におけるｃｃｒ５拮抗剤の使用
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
WO2017136820A2 (en) * 2016-02-06 2017-08-10 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017180389A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
RU2018140976A (ru) 2016-04-22 2020-05-22 Оби Фарма, Инк. Иммунотерапия рака путем иммунной активации или иммунной модуляции через антигены серии globo
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
US11136383B2 (en) 2016-10-26 2021-10-05 The Children's Medical Center Corporation Methods and compositions for modulaton of transforming growth factor beta-regulated functions
CN110290800A (zh) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
BR112019017120A8 (pt) 2017-02-17 2023-05-02 Hutchinson Fred Cancer Res Terapias de combinação para tratamento de cânceres e distúrbios autoimunes relacionados a bcma
JP7324710B2 (ja) 2017-02-21 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 肺癌の処置のための抗ｐｄ－１抗体
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
WO2019094265A1 (en) * 2017-11-10 2019-05-16 Armo Biosciences, Inc. Pd1 polypeptide binding molecules
WO2019092452A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
EP3768317A4 (en) 2018-03-22 2021-12-22 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
CA3097916A1 (en) 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
US10949272B2 (en) * 2018-06-14 2021-03-16 Microsoft Technology Licensing, Llc Inter-application context seeding
CN113038939A (zh) 2018-11-14 2021-06-25 瑞泽恩制药公司 损害内施用pd-1抑制剂用于治疗皮肤癌
EA202191556A1 (ru) 2018-12-03 2021-10-14 Фьюжн Фармасьютикалз Инк. Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
KR102167539B1 (ko) * 2018-12-28 2020-10-20 한국원자력의학원 방사선 치료 시 변화되는 암 세포의 면역관문인자 발현수준을 측정하는 단계를 포함하는 방사선 치료 예후 예측을 위한 정보제공방법 및 방사선 치료 병용 암 치료용 조성물
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN115776908A (zh) * 2020-05-12 2023-03-10 拉什大学医学中心 用于治疗癌症的组合物和方法
CN111925444B (zh) * 2020-08-19 2022-10-11 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
CN116490244A (zh) * 2020-11-18 2023-07-25 武田药品工业株式会社 Sting激动剂、检查点抑制剂和辐射的施用
WO2022178218A1 (en) 2021-02-19 2022-08-25 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
US9132281B2 (en) 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
CN102935228B (zh) * 2011-08-15 2015-02-18 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的试剂、其用途及方法
ES2808152T3 (es) * 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
NZ622452A (en) 2012-06-21 2017-10-27 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20160002731A1 (en) * 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
ES2721168T3 (es) 2013-01-11 2019-07-29 Dingfu Biotarget Co Ltd Agentes para tratar tumores, uso y método de los mismos
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

Also Published As

Publication number Publication date
US20190192655A1 (en) 2019-06-27
MX382472B (es) 2025-03-13
EP3157629A1 (en) 2017-04-26
RU2017101312A (ru) 2018-07-20
AU2023202654B2 (en) 2025-12-18
JP6877147B2 (ja) 2021-05-26
JP2023093538A (ja) 2023-07-04
JP2020121978A (ja) 2020-08-13
IL249133B (en) 2022-04-01
DK3157629T3 (da) 2022-12-19
MX2021004828A (es) 2021-09-21
TW202228777A (zh) 2022-08-01
TWI781021B (zh) 2022-10-11
AU2020210207B2 (en) 2023-02-02
RU2017101312A3 (es) 2019-01-29
KR20220082097A (ko) 2022-06-16
ES2933603T3 (es) 2023-02-10
SG11201610600SA (en) 2017-01-27
EP3157629B1 (en) 2022-10-05
WO2015193352A1 (en) 2015-12-23
JP7258981B2 (ja) 2023-04-17
KR20230113847A (ko) 2023-08-01
CA2950046A1 (en) 2015-12-23
US10092645B2 (en) 2018-10-09
AU2015276173B2 (en) 2020-08-20
RU2711408C2 (ru) 2020-01-17
SG10202108654PA (en) 2021-09-29
KR20170015460A (ko) 2017-02-08
PT3157629T (pt) 2022-12-20
AU2023202654A1 (en) 2023-05-18
AU2020210207A1 (en) 2020-08-20
KR102592781B1 (ko) 2023-10-20
TW201617093A (zh) 2016-05-16
BR112016028964A2 (pt) 2017-10-17
KR20240162170A (ko) 2024-11-14
PL3157629T3 (pl) 2023-01-30
JP2025028053A (ja) 2025-02-28
JP2017525661A (ja) 2017-09-07
JP2022031638A (ja) 2022-02-22
HUE060689T2 (hu) 2023-04-28
IL249133A0 (en) 2017-01-31
CN107073107A (zh) 2017-08-18
EP4144412A1 (en) 2023-03-08
AU2015276173A1 (en) 2016-12-22
US20160051672A1 (en) 2016-02-25
MX2021004821A (es) 2021-08-19
CA2950046C (en) 2023-02-14
TWI751101B (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
MX2016015346A (es) Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2025000380A (es) Metodos de tratamiento con farmacos del sustrato cyp3a4
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2019013862A (es) Terapia de combinacion.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MY189663A (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
PH12016502352A1 (en) Pharmaceutical composition
MX2020001727A (es) Terapia de combinacion.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX380835B (es) Terapia de combinación pac-1.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EP2786764A3 (en) Combination therapy using anti-c-met antibody and sorafenib
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
UA108546U (uk) Спосіб лікування хворих на лімфому ходжкіна іів стадії